Answers are grounded in this paper and cite their sources.
Assesses immunotherapy crossing blood-brain barrier in SHH medulloblastoma, suggesting clinical promise.
values (from 2.51 - 13.9 nM at 0.5 µM start concentration to 1.01 - 3.4 nM at 2 µM start concentration). Additionally, we could demonstrate that the generated IT can successfully cross the blood-brain barrier (BBB) in vitro in an in vitro BBB-model based on human brain microvascular endothelial (HBMEC) cells . These results suggest that this immunotherapeutic approach is a promising candidate for further development and clinical application.
No takes yet. Share an insight, caveat, or question.
Krüger et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: